(Q45073959)

9 December 2017

title

Rosiglitazone combined with insulin preserves islet beta cell function in adult-onset latent autoimmune diabetes (LADA). (English)

1 reference

9 December 2017

1 reference

1 reference

Zhiguang Zhou

1

1 reference

9 December 2017

Xia Li

2

1 reference

9 December 2017

Gan Huang

3

1 reference

9 December 2017

Jian Peng

4

1 reference

9 December 2017

Lin Yang

5

1 reference

9 December 2017

Xiang Yan

6

1 reference

9 December 2017

Jianping Wang

7

1 reference

9 December 2017

publication date

1 March 2005

1 reference

Diabetes - Metabolism: Research and Reviews

9 December 2017

published in

1 reference

9 December 2017

volume

21

1 reference

9 December 2017

issue

2

1 reference

9 December 2017

page(s)

203-208

1 reference

Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors

9 December 2017

cites work

1 reference

Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease

21 January 2018

1 reference

7 January 2021

Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency

1 reference

7 January 2021

Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): definition, characterization, and potential prevention

1 reference

7 January 2021

Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM.

1 reference

7 January 2021

Insulin intervention to preserve beta cells in slowly progressive insulin-dependent (type 1) diabetes mellitus

1 reference

7 January 2021

Slowly progressing type 1 diabetes: persistence of islet cell autoantibodies is related to glibenclamide treatment.

1 reference

7 January 2021

T-cell insulitis found in anti-GAD65+ diabetes with residual beta-cell function. A case report

1 reference

7 January 2021

Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence

1 reference

7 January 2021

Troglitazone stimulates pancreatic growth in normal rats

1 reference

7 January 2021

Troglitazone prevents insulin dependent diabetes in the non-obese diabetic mouse

1 reference

7 January 2021

Thiazolidinediones for the prevention of diabetes in the non-obese diabetic (NOD) mouse: implications for human type 1 diabetes

1 reference

7 January 2021

Detection of GAD65 antibodies in diabetes and other autoimmune diseases using a simple radioligand assay

1 reference

7 January 2021

A novel radioligand binding assay to determine diagnostic accuracy of isoform-specific glutamic acid decarboxylase antibodies in childhood IDDM

1 reference

7 January 2021

Prevention of vascular and neural dysfunction in diabetic rats by C-peptide.

1 reference

7 January 2021

Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with Type 1 diabetes mellitus

1 reference

7 January 2021

C-peptide: a new potential in the treatment of diabetic nephropathy

1 reference

7 January 2021

Amelioration of sensory nerve dysfunction by C-Peptide in patients with type 1 diabetes

1 reference

7 January 2021

Insulin-sensitizing agents--thiazolidinediones (glitazones).

1 reference

7 January 2021

Where thiazolidinediones will fit.

1 reference

7 January 2021

Glutamate decarboxylase antibody levels predict rate of beta-cell decline in adult-onset diabetes

1 reference

7 January 2021

Titre and combination of ICA and autoantibodies to glutamic acid decarboxylase discriminate two clinically distinct types of latent autoimmune diabetes in adults (LADA).

1 reference

7 January 2021

Interleukin (IL)-4 indirectly suppresses IL-2 production by human T lymphocytes via peroxisome proliferator-activated receptor gamma activated by macrophage-derived 12/15-lipoxygenase ligands

1 reference

7 January 2021

The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses

1 reference

7 January 2021

Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT.

1 reference

7 January 2021

The nuclear receptor PPAR gamma is expressed by mouse T lymphocytes and PPAR gamma agonists induce apoptosis

1 reference

7 January 2021

Inhibition of the transcription factors AP-1 and NF-kappaB in CD4 T cells by peroxisome proliferator-activated receptor gamma ligands

1 reference

7 January 2021

Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis

1 reference

7 January 2021

A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model

1 reference

7 January 2021

PPARgamma and inflammatory bowel disease: a new therapeutic target for ulcerative colitis and Crohn's disease

1 reference

7 January 2021

A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response

1 reference

7 January 2021

Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor-gamma

1 reference

7 January 2021

Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis

1 reference

7 January 2021

Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis

1 reference

7 January 2021

Prevention of autoimmune diabetes in NOD mice by troglitazone is associated with modulation of ICAM-1 expression on pancreatic islet cells and IFN-γ expression in splenic T cells

1 reference

7 January 2021

Expression of peroxisome proliferator-activated receptor γ (PPARγ) in normal human pancreatic islet cells

1 reference

7 January 2021

Identifiers

DOI

10.1002/DMRR.503

1 reference

9 December 2017

1 reference